Methicillin-Resistant Staphylococcus aureus has Phenotypic Variation in mecA Expression that Alters Antibiotic

Dongzhu Ma1, Rekha Arya1, Beth Ann Knapick1

  • 1Arthritis and Arthroplasty Design Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA.

Insights

Methicillin-resistant Staphylococcus aureus (MRSA) can become sensitive to beta-lactam antibiotics like cefazolin in physiological environments, challenging resistance assumptions. This discovery offers new therapeutic targets for treating dangerous MRSA infections.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) sepsis presents significant morbidity and mortality.
  • Clinical studies suggest dual antibiotic therapy, including beta-lactams, improves MRSA sepsis outcomes, despite MRSA's inherent resistance.
  • This study investigates the paradoxical observation of MRSA sensitivity to beta-lactams in specific physiological conditions.

Purpose of the Study:

  • To explore the phenotypic variation in MRSA's mecA expression and PBP2a protein levels.
  • To investigate the role of environmental conditions in altering MRSA's beta-lactam antibiotic sensitivity.
  • To identify novel therapeutic targets for combating multidrug-resistant bacteria.

Main Methods:

  • Quantitative RT-PCR and Western blotting to assess mecA expression and PBP2a levels.
  • Culturing MRSA in physiological media (fetal bovine serum, synovial fluid) versus standard media (MHB).
  • Whole genome sequencing of MRSA mutants and cell wall peptidoglycan analysis.

Main Results:

  • MRSA exhibited reduced mecA expression and PBP2a protein levels in physiological media compared to MHB.
  • Phenotypic variation in beta-lactam sensitivity was observed across clinical MRSA isolates.
  • Genes including clp family proteins and rpo genes, along with WTA glycosylation, were implicated in altered beta-lactam resistance.

Conclusions:

  • Environmental conditions significantly influence MRSA's phenotypic expression of antibiotic resistance.
  • The study provides a potential explanation for the clinical efficacy of beta-lactams in MRSA sepsis treatment.
  • Targeting pathways involving clpP, rpoB, and WTA glycosylation presents promising strategies for new MRSA therapies.